Younger patients with acute lymphoblastic leukemia who do not respond to CD19-directed chimeric antigen receptor T-cell therapy exhibit certain gene regulation patterns that may be associated with treatment resistance, study results show.
Data from multi-omic analysis conducted by researchers at NCI and presented at American Association for Cancer Research Annual Meeting suggest there are potential clinical biomarkers that can be used to determine which patients may not respond to CD19-directed CAR-T cell therapy prior to treatment.
B-cell ALL is the most common cancer among children but is